TG Therapeutics Inc
TGTXBuild a strategy around TGTX
TG Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Net margin 84% TTM vs industry median 0% driven by $360M deferred tax benefit - non-recurring, masks -70M operating cash burn[Net Margin TTM]
- EPS growth 120.5% 1Y while revenue 3Y CAGR only 11% - margin expansion from BRIUMVI launch, not sustainable volume growth[EPS Growth 1Y]
- ROE 112% TTM and ROIC 68% TTM vastly exceed industry (median ROE -39%) - capital efficiency inflection point[ROE TTM]
Watch Triggers
- Operating Cash Flow TTM: Turns positive for 2 consecutive quarters — Validates commercial model sustainability without dilution
- Accounts Receivable: A/R days exceed 200 or grows faster than revenue — Signals collection issues or channel stuffing risk
- Cash and Equivalents: Falls below $50M without financing announcement — Forces dilutive equity raise at potentially unfavorable terms
Bull Case
Gross margin 85% TTM with 79% gross profit growth 1Y demonstrates pricing power and commercial traction for BRIUMVI in MS market
Operating margin 19% TTM vs industry median 0% shows leverage emerging; P/E 10.8x vs industry 20x suggests market discounts sustainability
Bear Case
Net debt $171M with FCF -70M TTM and only $74M cash creates 12-month liquidity risk requiring dilution or debt raise
A/R at 50% of revenue ($265M) signals aggressive revenue recognition or collection challenges - working capital trap
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage TGTX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash burn will persist 12-18 months until BRIUMVI revenue scales to cover $143M R&D spend
- FCF -70M TTM with only $74M cash on hand
- A/R of $265M suggests revenue recognition ahead of collections
- R&D at 27% of revenue vs industry median 170%
Valuation Context
Caveats
Public Strategies Rankings
See how TG Therapeutics Inc ranks across different investment strategies.
Leverage TGTX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
TGTX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$5.32B | — | ||
$5.5B | — | ||
12 | — | ||
$616.29M | +87.3% | — | |
$2.77 | +1746.7% | — | |
20.0% | +7.3% | — | |
72.6% | +65.5% | — | |
$-24.99M | — | ||
103% | +90.5% | — | |
Beta 5Y (Monthly) | unknown | — |
TGTX Dividend History
TGTX Stock Splits
TGTX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
02/27/26 | 12/31/25 | Unknown | |
11/05/25 | 09/30/25 | 10-Q | |
08/08/25 | 06/30/25 | 10-Q | |
05/09/25 | 03/31/25 | 10-Q | |
03/03/25 | 12/31/24 | Unknown | |
11/07/24 | 09/30/24 | 10-Q | |
08/09/24 | 06/30/24 | 10-Q | |
05/06/24 | 03/31/24 | 10-Q | |
02/29/24 | 12/31/23 | 10-K | |
11/06/23 | 09/30/23 | Unknown | |
08/04/23 | 06/30/23 | 10-Q | |
05/08/23 | 03/31/23 | 10-Q | |
03/01/23 | 12/31/22 | 10-K | |
11/09/22 | 09/30/22 | 10-Q | |
08/09/22 | 06/30/22 | 10-Q | |
05/10/22 | 03/31/22 | 10-Q | |
03/01/22 | 12/31/21 | 10-K | |
11/08/21 | 09/30/21 | 10-Q | |
08/06/21 | 06/30/21 | 10-Q | |
05/10/21 | 03/31/21 | 10-Q | |
03/01/21 | 12/31/20 | 10-K | |
11/09/20 | 09/30/20 | 10-Q | |
08/10/20 | 06/30/20 | 10-Q | |
05/11/20 | 03/31/20 | 10-Q | |
03/02/20 | 12/31/19 | 10-K | |
11/12/19 | 09/30/19 | 10-Q | |
08/09/19 | 06/30/19 | 10-Q | |
05/10/19 | 03/31/19 | 10-Q | |
03/01/19 | 12/31/18 | 10-K | |
11/09/18 | 09/30/18 | 10-Q | |
08/09/18 | 06/30/18 | 10-Q | |
05/10/18 | 03/31/18 | 10-Q | |
03/15/18 | 12/31/17 | 10-K | |
11/09/17 | 09/30/17 | 10-Q | |
08/09/17 | 06/30/17 | 10-Q | |
05/10/17 | 03/31/17 | 10-Q | |
03/16/17 | 12/31/16 | 10-K | |
11/09/16 | 09/30/16 | 10-Q | |
08/09/16 | 06/30/16 | 10-Q | |
05/10/16 | 03/31/16 | 10-Q | |
03/15/16 | 12/31/15 | 10-K | |
11/09/15 | 09/30/15 | 10-Q | |
08/10/15 | 06/30/15 | 10-Q | |
05/11/15 | 03/31/15 | 10-Q | |
03/16/15 | 12/31/14 | 10-K | |
11/14/14 | 09/30/14 | 10-Q | |
07/24/14 | 06/30/14 | 10-Q | |
05/14/14 | 03/31/14 | 10-Q | |
03/07/14 | 12/31/13 | 10-K | |
11/14/13 | 09/30/13 | 10-Q | |
08/09/13 | 06/30/13 | 10-Q | |
05/14/13 | 03/31/13 | 10-Q | |
03/21/13 | 12/31/12 | 10-K | |
11/14/12 | 09/30/12 | 10-Q | |
08/09/12 | 06/30/12 | 10-Q | |
05/14/12 | 03/31/12 | 10-Q | |
03/14/12 | 12/31/11 | 10-K | |
11/14/11 | 09/30/11 | 10-Q | |
08/15/11 | 06/30/11 | 10-Q | |
05/16/11 | 03/31/11 | 10-Q | |
03/31/11 | 12/31/10 | 10-K | |
11/15/10 | 09/30/10 | 10-Q | |
08/16/10 | 06/30/10 | 10-Q | |
05/24/10 | 03/31/10 | 10-Q | |
03/31/10 | 12/31/09 | 10-K | |
11/16/09 | 09/30/09 | 10-Q | |
08/14/09 | 06/30/09 | 10-Q | |
05/15/09 | 03/30/09 | 10-Q | |
03/31/09 | 12/31/08 | 10-K | |
11/19/08 | 09/30/08 | NT 10-Q | |
08/19/08 | 06/30/08 | NT 10-Q | |
05/20/08 | 03/30/08 | Unknown | -- |
03/31/08 | 12/31/07 | 10-K | |
11/14/07 | 09/30/07 | 10-Q | |
08/14/07 | 06/30/07 | 10-Q | |
05/15/07 | 03/31/07 | 8-K | |
12/31/06 | 12/31/06 | 10KSB | |
09/30/06 | 09/30/06 | 10QSB | |
06/30/06 | 06/30/06 | 10QSB | |
03/31/06 | 03/30/06 | Unknown | -- |
12/31/05 | 12/31/05 | 10KSB | |
09/30/05 | 09/30/05 | 10QSB | |
06/30/05 | 06/30/05 | 10QSB | |
03/31/05 | 03/31/05 | 4 | |
12/31/04 | 12/31/04 | 10KSB | |
09/30/04 | 09/30/04 | 10QSB | |
06/30/04 | 06/30/04 | 10QSB | |
03/31/04 | 03/30/04 | Unknown | -- |
12/31/03 | 12/31/03 | 10KSB | |
09/30/03 | 09/30/03 | 10QSB | |
06/30/03 | 06/30/03 | 10QSB | |
03/31/03 | 03/30/03 | Unknown | -- |
12/31/02 | 12/31/02 | NT 10-K | |
09/30/02 | 09/30/02 | 10QSB | |
06/30/02 | 06/30/02 | 10QSB | |
03/31/02 | 03/30/02 | Unknown | -- |
12/31/01 | 12/31/01 | 5 | |
09/30/01 | 09/30/01 | NT 10-Q | |
08/20/01 | 06/30/01 | NT 10-Q | |
03/31/01 | 03/30/01 | Unknown | -- |
12/31/00 | 12/31/00 | NT 10-K | |
09/30/00 | 09/30/00 | NT 10-Q | |
06/30/00 | 06/30/00 | NT 10-Q | |
03/31/00 | 03/30/00 | Unknown | -- |